GLP-1/GIP co-agonists are one of the most promising drugs to treat obesity and diabetes and have been shown to reduce fasting cholesterol and triglycerides in T2D patients. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.